業聚醫療(06929.HK)2025年中期業績:收入及純利雙雙增長分別達8360萬美元及1980萬美元 擬宣派特別股息每股15港仙
(香港,2025年8月15日)—專營經皮冠狀動脈介入治療(PCI)及經皮腔內血管成形術(PTA)手術介入器械的全球醫療器械製造公司業聚醫療(06929.HK)今天宣佈截至2025年6月30日止六個月的中期業績。儘管宏觀經濟環境未見明朗,集團的收入及純利仍雙雙錄得增長。
美國市場增長強勁,加上亞太地區及歐洲、中東與非洲地區新興市場的持續貢獻,推動集團收入達到83.6百萬美元,較去年同期上升5.9%。核心經營利潤為15.1百萬美元,同比增長11.4%。公司擁有人應占利潤同比上升5.1%至19.8百萬美元。每股基本盈利為2.40美仙(2024年上半年:2.28美仙)。
截至2025年6月30日,集團財務狀況保持穩健,現金及銀行結餘達237.1百萬美元。監於集團的財務狀況穩健,以及為慶祝成立25週年,董事會議決宣派特別現金股息每股普通股15港仙,彰顯集團致力為股東創造價值。連同截至2024年12月31日止年度的末期股息每股10港仙(已於2025年6月16日派付),股東於2025年合共獲派股息每股25港仙。
業聚醫療董事長、執行董事兼首席執行官錢永勛先生表示:「過去25年,我們持續投資於創新及全球商業化能力,除了為業聚醫療建立了聲譽,也助我們在不同的經濟週期中破浪前行。儘管2025年上半年面臨宏觀經濟及地緣政治的雙重挑戰,我們的全球佈局仍展現韌性。美國市場增長印證了市場對我們的優質產品需求殷切,而我們亦透過龐大的銷售網絡,成功把握了亞太地區及歐洲、非洲及中東地區的增長機遇。我們將繼續透過直銷市場覆蓋、卓越的銷售支援、對創新的投入,以及全面的PCI和PTA產品組合提升品牌價值,從而強化競爭優勢,為醫生及患者提供更安全有效治療方案的同時,也為股東創造長遠回報。」
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.